Involvement of Microphthalmia in the Inhibition of Melanocyte Lineage Differentiation and of Melanogenesis by Agouti Signal Protein*
- Edith Aberdam‡,
- Corine Bertolotto‡,
- Elena V. Sviderskaya§,
- Virginie de Thillot‡,
- Timothy J. Hemesath¶,
- David E. Fisher¶,
- Dorothy C. Bennett§,
- Jean-Paul Ortonne‡ and
- Robert Ballotti‡‖
- From the ¶Division of Pediatric Hematology/Oncology, Children’s Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, §St. George’s Hospital Medical School, London SW17 ORE, United Kingdom, and‡INSERM U385, Biologie et Physiopathologie de la Peau, Faculté de Médecine, 06107 Nice Cedex 2, France
Abstract
In mouse follicular melanocytes, production of eumelanins (brown-black pigments) and pheomelanins (yellow-brownish pigments) is under the control of two intercellular signaling molecules that exert opposite actions, α-melanocyte-stimulating hormone (αMSH) which preferentially increases the synthesis of eumelanins, and agouti signal protein (ASP) whose expression favors the production of hair containing pheomelanins. In this study, we report that ASP does not only affect mature melanocytes but can also inhibit the differentiation of melanoblasts. We show that both αMSH and forskolin promote the differentiation of murine melanoblasts into mature melanocytes and that ASP inhibits this process. We present evidence that the expression of a specific melanogenic transcription factor, microphthalmia, and its binding to an M box regulatory element, is inhibited by ASP. We also show that, in B16 murine melanoma cells, ASP inhibits αMSH-stimulated expression of tyrosinase, tyrosine-related proteins 1 and 2 through an inhibition of the transcription activity of their respective promoters. Further, ASP inhibits αMSH-induced expression of the microphthalmia gene and reduces the level of microphthalmia in the cells. Our data demonstrate that ASP can regulate both melanoblast differentiation and melanogenesis, pointing out the key role of microphthalmia in the control of these processes.
Footnotes
-
↵* This work was supported by La Ligue Nationale Contre le Cancer and Association pour la Recherche sur le Cancer (Grant 8402).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
↵‖ To whom correspondence should be addressed: INSERM U385, Biologie et Physiopathologie de la Peau, Faculté de Médecine, Avenue de Valombrose 06107, Nice Cedex 2, France. Tel.: (33) 4 93 37 77 90; Fax: (33) 4 93 81 14 04; E-mail:ballotti{at}unice.fr.
-
↵1 The abbreviations used are: TRP, tyrosinase-related protein; ASP, agouti signal protein; αMSH, α-melanocyte-stimulating hormone; mi, microphthalmia; bFGF, basic fibroblast growth factor; MC1R, melanocortin 1 receptor; PAGE, polyacrylamide gel electrophoresis.
-
- Received March 26, 1998.
- Revision received May 22, 1998.
- The American Society for Biochemistry and Molecular Biology, Inc.











